Clinical Trial Update: Study of Nab-Paclitaxel in High Risk Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for nab-paclitaxel in high-risk early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED